Welcome to our dedicated page for Centene Del SEC filings (Ticker: CNC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Centene Corporation filings document operating and financial disclosures for a government-focused managed care company. Form 8-K reports furnish quarterly results press releases, GAAP and adjusted EPS guidance, non-GAAP financial measure disclosures, conference-related Regulation FD updates and material-event reports tied to company performance.
Centene's proxy and governance filings cover annual meeting matters, board and executive compensation disclosures, equity awards, officer appointments and related corporate governance topics. Other filings address material agreements, forward-looking-statement disclosures and formal exhibits filed or furnished with the SEC.
Centene Corp director Lauren M. Tyler filed an initial Form 3 indicating no securities beneficially owned in the company. The filing shows zero shares held directly after the reported position. This is a baseline ownership disclosure rather than a buy or sell transaction.
Centene Corporation has expanded its Board of Directors from nine to ten members and appointed Lauren M. Tyler as a director effective June 19, 2026, with a term running through the 2027 annual meeting of stockholders.
She is expected to join the Audit Committee and the Compensation and Talent Committee on July 1, 2026. Tyler brings more than 30 years of leadership experience, including senior roles at JPMorgan Chase & Co., and currently serves on the boards of Cencora, Inc. and Guardian Life. She will receive compensation under Centene’s standard non-employee director program, and the company issued a press release describing her appointment.
Centene Corp Chief Operating Officer Susan Raye Smith reported a tax-related share disposition linked to equity compensation. On this Form 4, 483 shares of Centene common stock were withheld at $65.19 per share to cover taxes upon vesting of a previously reported restricted stock unit grant.
After this tax-withholding disposition, Smith directly owns 212,237 shares of Centene common stock. Her ownership also includes 181,082 shares tied to previously granted restricted stock units and performance stock units, which remain subject to vesting requirements.
Centene Corp director Kenneth A. Burdick reported an open-market sale of 80,000 shares of Centene common stock at $64.55 per share. A footnote explains that the weighted average sale price reflects trades between $64.55 and $64.61 per share, with detailed breakdowns available on request.
Following this sale, Burdick directly holds 197,085.924 Centene shares, which include 3,992 restricted stock units subject to vesting requirements. Separately, 86,498 Centene shares are held indirectly by the Burdick Family LLC, where he is a chief manager but disclaims beneficial ownership beyond his pecuniary interest.
Centene Group President Michael A. Carson reported a discretionary transaction involving phantom stock tied to Centene common shares. He reallocated 604.004 phantom stock units under the company’s nonqualified deferred compensation plan from an investment option tracking Centene stock to an alternative investment option, at a reference price of $59.60 per share. The filing states this did not involve any open market sale of securities.
Following the update, Carson reports ownership of 122,882 shares of common stock directly and 825 shares indirectly through his spouse. His holdings include 113,747 previously granted restricted stock units and performance stock units that remain subject to vesting. The phantom stock will be settled in cash or other non‑Centene securities upon his termination or another date he elects.
Centene Group President Michael A. Carson increased his deferred compensation exposure by acquiring 47.935 shares of phantom stock at $57.7700 per unit. Each phantom share represents the right to receive the fair market value of one Centene common share.
The phantom stock was obtained through regularly scheduled payroll contributions to the company’s deferred compensation plan and has no formal expiration date. After this award, Carson holds 604.004 phantom stock units, 122,882 shares of common stock held directly (including 113,747 restricted and performance stock units subject to vesting), and 825 common shares held indirectly by his spouse.
Centene Corporation executive Daniel P. Finke, Group President, Markets & Comm, has filed an initial ownership report showing compensation-based equity holdings in the company. The filing lists 228,127 restricted stock units, which are scheduled to vest in three equal installments on each anniversary of the grant date beginning April 15, 2027. These holdings represent stock-based awards rather than recent open-market share purchases or sales.
Centene Corp executive Michael A. Carson filed a Form 3 disclosing his initial equity interests in the company. He reports direct ownership of 122,882 shares of common stock and indirect ownership of 825 shares held by his spouse. He also holds 556.069 units of phantom stock, each linked to the value of one Centene common share and acquired through payroll contributions to the company’s deferred compensation plan.
Carson’s ownership further includes 57,619 previously awarded restricted stock units that vest between October 15, 2026 and March 15, 2027, and 56,128 performance stock units subject to three-year performance conditions, with potential vesting from 0% to 200% of target based on the company’s performance.
Centene Corporation reported the results of its annual shareholder meeting, where 412,968,059 shares of common stock were represented. All nine director nominees were elected, each receiving significantly more votes “for” than “against.”
Stockholders approved, on a non-binding advisory basis, the Company’s executive compensation, and ratified KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. A shareholder proposal requesting an independent board chairman did not pass. The Board also confirmed the executive officer team, including Sarah London as Chief Executive Officer and newly appointed group presidents Daniel Finke (Medicaid and Marketplace) and Michael Carson (Medicare and Specialty).